Medical organization Alpha Sigma introduces two novel healthcare items

In the consumer healthcare sector, Alfasigma, a company based in Munich, has recently entered the over-the-counter (OTC) market with the launch of two new products: Esoxx One and Esoxx Reflux Defence, both designed to provide relief for those suffering from reflux and heartburn symptoms.

Esoxx Reflux Defence is a chewable tablet containing chondroitin sulfate, hyaluronic acid, and magnesium trisilicate. This combination works to protect the mucous membranes of the esophagus and stomach by neutralizing stomach acid and promoting the repair of damaged mucous membranes. Esoxx One, on the other hand, is a ready-to-drink syrup in single-dose sachets. It has protective properties, forming a long-lasting, adherent protective film on the mucous membrane of the esophagus. Both products are intended for adults and children aged 12 and above.

Esoxx One has been shown to provide relief within 30 minutes, as shown in a study. It is also suitable for use during pregnancy and breastfeeding, but it is always advisable to consult a doctor before starting any new medication. The active ingredient combination in Esoxx Reflux Defence can be used in combination with proton pump inhibitors (PPIs).

Stada, another German-based company, is planning an Initial Public Offering (IPO) in the autumn. In contrast, Alfasigma's stock has fallen to a two-year low. Meanwhile, Alfasigma has also launched other products in the consumer health sector in Germany in the spring, including macrogol preparations and probiotics.

Interestingly, Öko-Test recently rated teething gels as "insufficient". However, neither Esoxx One nor Esoxx Reflux Defence have been rated by Öko-Test yet.

As for Rennie, a well-known brand in the digestive health sector, Sugar-free Rennie Fresh has been released. It is yet to be seen how this new product will fare in the market.

In conclusion, Alfasigma's entry into the OTC market with Esoxx One and Esoxx Reflux Defence marks a significant step in the consumer healthcare sector. These new products, approved for adults and children aged 12 and above, offer relief from symptoms of gastroesophageal reflux disease (GERD) and provide protection for the mucous membranes of the esophagus and stomach.